BiotechTube

DSP-0390

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glioma, Malignant

Conditions

Glioma, Malignant, Grade II Glioma, IDH Mutation

Trial Timeline

Apr 3, 2025 → May 17, 2026

NCT ID
NCT06636162

About DSP-0390

DSP-0390 is a phase 1 stage product being developed by Sumitomo Pharma for Glioma, Malignant. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06636162. Target conditions include Glioma, Malignant, Grade II Glioma, IDH Mutation.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT06636162Phase 1Recruiting
NCT05023551Phase 1Active

Competing Products

20 competing products in Glioma, Malignant

See all competitors
ProductCompanyStageHype Score
TemozolomideNovocurePhase 1
28
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
33
LY2157299 + LomustineEli LillyPhase 1
33
DS-1001bDaiichi SankyoPhase 2
52
DS-1001bDaiichi SankyoPhase 1
33
Perampanel + Standard of CareEisaiPhase 1/2
41
Temozolomide and BevacizumabEisaiPhase 2
52
TemozolomideEisaiPhase 2
52
Gliadel Wafer + TemozolomideEisaiPhase 2
52
Palonosetron (PALO)EisaiPhase 2
52
Gliadel/Avastin/CPT-11EisaiPhase 2
52
Lenvatinib + BevacizumabEisaiPhase 2
52
Granisetron + OndansetronKyowa KirinPhase 2
52
Binimetinib 15 MGOno PharmaceuticalPhase 2
52
EnzastaurinEli LillyPhase 2
52
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
33
LY2157299 + Radiation + TemozolomideEli LillyPhase 1/2
41
Abemaciclib + TemozolomideEli LillyPhase 2
52
DSP-0390Sumitomo PharmaPhase 1
33
ApatinibJiangsu Hengrui MedicinePhase 2
52

Other Products from Sumitomo Pharma

BlonanserinApproved
85
Mosapride + domperidoneApproved
85
levalbuterol HCl + albuterol SulfateApproved
85
LurasidoneApproved
85
placebo, isotonic ciclesonide, hypotonic ciclesonideApproved
85